Core Insights - Pfizer Inc. and Astellas Pharma U.S. Inc. announced final overall survival results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide) for men with non-metastatic hormone-sensitive prostate cancer [1] Group 1 - The EMBARK study assessed XTANDI® in combination with leuprolide and as monotherapy [1] - The target patient population includes men with non-metastatic hormone-sensitive prostate cancer who have biochemical recurrence [1]